US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Dynavax in clover on Covid-19 vaccine data
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
Valneva falls as UK contract axe falls
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
Another gene therapy safety scare hits
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
Bavarian Nordic gets a vaccine booster
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
